In vitro activities of voriconazole, itraconazole, and amphotericin B against blastomyces dermatitidis, coccidioides immitis, and histoplasma capsulatum

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 6, 2000, Pages 1734-1736

  Li, Ren Kai ^a   Ciblak, Meral A ^a   Nordoff, Nicole ^b   Pasarell, Lester ^b   Warnock, David W ^a,c   Mcginnis, Michael R ^b  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; BLASTOMYCES DERMATITIDIS; COCCIDIOIDES IMMITIS; DRUG POTENCY; FUNGICIDAL ACTIVITY; HISTOPLASMA CAPSULATUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BLASTOMYCES; COCCIDIOIDES; HISTOPLASMA; HUMANS; ITRACONAZOLE; PYRIMIDINES; TRIAZOLES;

EID: 0034037292     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.6.1734-1736.2000     Document Type: Article

References (19)

1. Clancy, C. J., and M. H. Nguyen. 1998. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis. 17:573-575.
2. Cuenca-Estrella, M., B. Ruiz-Diez, J. V. Martinez-Suarez, A. Monzon, and J. L. Rodriguez-Tudela. 1999. Comparative in-vitro activity of voriconazole (UK-109-496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J. Antimicrob. Chemother. 43:149-151.
3. Espinel-Ingroff, A. 1998. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36:198-202.
4. Espinel-Ingroff, A., M. Bartlett, R. Bowden, N. X. Chin, C. Cooper, A. Fothergill, M. R. McGinnis, P. Menezes, S. A. Messer, P. W. Nelson, F. C. Odds, L. Pasarell, J. Peter, M. A. Pfaller, J. H. Rex, M. G. Rinaldi, G. S. Shankland, T. J. Walsh, and I. Weitzman, 1997. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J. Clin. Microbiol. 35:139-143.
5. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical use. Rev. Infect. Dis. 12:308-329.
6. Johnson, E. M., A. Szekely, and D. W. Warnock. 1998. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J. Antimicrob. Chemother. 42:741-745.
7. Kauffman, C. A. 1996. Role of azoles in antifungal therapy. Clin. Infect. Dis. 22(Suppl. 2):S148-S153.
8. Kauffman, C. A., and L. T. Zarins. 1998. In vitro activity of voriconazole against Candida species. Diagn. Microbiol. Infect. Dis. 31:297-300.
9. McGinnis, M. R., L. Pasarell, D. A. Sutton, A. W. Fothergill, C. R. Cooper, and M. G. Rinaldi. 1997. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob. Agents Chemother. 41:1832-1834.
10. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
11. Nguyen, M. H., C. J. Clancy, V. L. Yu, Y. C. Yu, A. J. Morris, D. R. Snydman, D. A. Sutton, and M. G. Rinaldi. 1998. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J. Infect. Dis. 177:425-430.
12. Nguyen, M. H., and C. Y. Yu. 1998. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates. Antimicrob. Agents Chemother. 42:471-472.
13. Oakley, K. L., C. B. Moore, and D. W. Denning. 1998. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J. Antimicrob. Chemother. 42:91-94.
14. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, G. V. Doern, M. E. Brandt, and R. A. Hajjeh. 1998. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob. Agents Chemother. 42:3242-3244.
15. Radford, S. A., E. M. Johnson, and D. W. Warnock. 1997. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob. Agents Chemother. 41:841-843.
16. Sutton, D. A., S. E. Sanche, S. G. Revankar, A. W. Fothergill, and M. G. Rinaldi. 1999. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J. Clin. Microbiol. 37;2343-2345.
17. Verweij, P. E., M. Mensink, A. J. M. M. Rijs, J. P. Donnelly, J. F. G. M. Meis, and D. W. Denning. 1998. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J. Antimicrob. Chemother. 42:389-392.
18. Walsh, T. J., G. P. Melcher, M. G. Rinaldi, J. Lecciones, D. McGough, J. Lee, D. Callender, M. Rubin, and P. A. Pizzo. 1990. Disseminated trichosporonosis resistant to amphotericin B. J. Clin. Microbiol. 28:1616-1622.
19. Wong-Beringer, A., R. A. Jacobs, and B. J. Guglielmo. 1998. Lipid formulations of amphotericin B: clinical efficacies and toxicities. Clin. Infect. Dis. 27:603-618.